Health
AstraZeneca reports positive late-stage trial results for experimental lung disease biologic
CNBC reports that AstraZeneca announced full trial data showing tozorakimab reduced severe flare-ups in chronic lung disease patients.
The short version
- AstraZeneca released full Phase 3 trial data indicating its experimental drug tozorakimab reduced flare-ups in chronic obstructive pulmonary disease patients.[CNBC]
- The treatment lowered moderate and severe exacerbations in both former smokers and a broader group of current and former smokers.[CNBC]
- Following the trial results, AstraZeneca raised its projected peak annual revenue for the drug to more than $5 billion.[CNBC]
- The biologic remains under FDA priority review, with an approval decision anticipated in early 2027.[CNBC]
Key facts
- AstraZeneca published full results from two late-stage clinical trials evaluating its experimental COPD therapy, tozorakimab.[CNBC]
- Tozorakimab reduced moderate and severe exacerbations by 29% and 34% among former smokers compared to placebo.[CNBC]
- In a broader trial population including current smokers, the drug cut moderate and severe flare-ups by 30% and 29%.[CNBC]
- The drug is undergoing FDA priority review, with a potential U.S. approval decision anticipated in the first quarter of 2027.[CNBC]
- AstraZeneca increased its peak annual sales projection for the medication to over $5 billion.[CNBC]
What remains uncertain
- How tozorakimab compares directly to existing biologics remains uncertain because no head-to-head clinical trials have evaluated them.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.